A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators Source: Eur Respir Rev, 27 (148) 170124; 10.1183/16000617.0124-2017 Year: 2018
From Bench to edside: Development of a drug to treat lung disease from a basic research start Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis Year: 2009
LSC - 2018 - In vivo models of Drug Induced ILD; tools to study and improve drug safety Source: International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment Year: 2018
PET/CT in nononcological lung diseases: current applications and future perspectives Source: Eur Respir Rev 2016; 25: 247-258 Year: 2016
Clinical use of new and repurposed drugs: the role and contribution of the ERS collaborative projects Source: International Congress 2017 – In the frontline of the fight against tuberculosis Year: 2017
Characterisation of clinical phenotypes is mandatory for the development of new drugs Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014
Biomarker discovery, development, and implementation in interstitial lung diseases Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options Year: 2021
Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008
Lung function testing in the COVID era: safety concerns you should consider Source: COVID-19 Videos Year: 2020
Precision medicine for lung cancer: new targeted treatments Source: International Congress 2017 – Precision medicine approaches in lung cancer Year: 2017
Modern molecular lung cancer diagnostics – how to use and interpret it wisely Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy Year: 2018
Monitoring asthma – state-of-the-art physiological, imaging, and biomarker assessments Source: International Congress 2015 – PG2 Asthma and COPD Year: 2015
Human small airway-on-a-chip: A novel microphysiological system to model lung inflammation, accelerate drug development and enable inhalational toxico-analysis Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016
Monitoring asthma - state-of-the-art physiological, imaging and biomarker assessments Source: International Congress 2018 – PG1 Asthma and chronic obstructive pulmonary disease Year: 2018
Drug development: news from “hot” early stage clinical trials: personalised immunotherapy for lung cancer Source: International Congress 2017 – Scientific year in review Year: 2017
Interferon-? liposome: a new system to improve drug delivery in the treatment of lung cancer Source: ERJ Open Res, 7 (3) 00555-2020; 10.1183/23120541.00555-2020 Year: 2021
Current place and future of immunotherapy in lung cancer Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies? Year: 2016